水素水摂取が非アルコール性脂肪肝疾患患者の肝脂肪蓄積および肝酵素プロファイルに与える影響：無作為化対照パイロット試験
A double-blind, placebo-controlled crossover trial enrolled 12 overweight outpatients with mild-to-moderate non-alcoholic fatty liver disease (NAFLD; mean age 56.2 years, BMI 37.7 kg/m²). Participants consumed either 1 L/day of hydrogen-rich water (HRW) or placebo water for 28 days. Dual-echo MRI assessment showed that HRW significantly reduced hepatic fat accumulation across individual liver regions-of-interest compared with placebo (P < 0.05). Liver fat content declined from 284.0 ± 118.1 mM to 256.5 ± 108.3 mM (2.9% reduction; 95% CI: 0.5–5.5). Serum aspartate transaminase levels fell by 10.0% (95% CI: −23.2 to 3.4). No significant between-group differences were detected for body weight or overall body composition. These preliminary findings suggest that HRW may have a beneficial role in modulating hepatic lipid accumulation and liver enzyme activity in NAFLD, warranting larger confirmatory trials.
Molecular hydrogen is proposed to improve lipid and glucose metabolism, thereby reducing hepatic fat deposition and lowering aspartate transaminase levels as a marker of hepatocellular stress.
Hydrogen-rich water is a low-risk delivery route, but the achievable systemic hydrogen dose is bounded. For clinical applications, inhalation is the most efficient route; inhalation, however, carries explosion risk, and concentration matters (empirical LFL of 10% applies to inhalation environments; high-concentration devices are documented in the Consumer Affairs Agency accident database and are not recommended).
See also:
https://h2-papers.org/en/papers/30982748